Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Philip Chaikin"'
Autor:
Philip Chaikin, Anja Welihozkiy
Publikováno v:
Case Reports in Veterinary Medicine, Vol 2018 (2018)
This case report documents the clinical and pathologic findings in a 12-year-old terrier mix with intraocular and splenic hemangiosarcoma. Pathologic findings in both the spleen and globe were consistent with hemangiosarcoma with a low mitotic count.
Externí odkaz:
https://doaj.org/article/83f4e7d134ca486fad332a8f636328b0
Autor:
Philip Chaikin, Sudhakar M. Pai
Publikováno v:
Journal of clinical pharmacologyReferences. 62(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2ee5d38411a52f16b6e2085d05650dd
https://pubmed.ncbi.nlm.nih.gov/35348233
https://pubmed.ncbi.nlm.nih.gov/35348233
Autor:
Anja Welihozkiy, Philip Chaikin
Publikováno v:
Case Reports in Veterinary Medicine, Vol 2018 (2018)
Case Reports in Veterinary Medicine
Case Reports in Veterinary Medicine
This case report documents the clinical and pathologic findings in a 12-year-old terrier mix with intraocular and splenic hemangiosarcoma. Pathologic findings in both the spleen and globe were consistent with hemangiosarcoma with a low mitotic count.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e01a2d56ba10e04a25cd80c554d98eb
https://doi.org/10.1155/2018/6160980
https://doi.org/10.1155/2018/6160980
Autor:
Philip Chaikin
Publikováno v:
The Journal of Clinical Pharmacology. 57:690-703
BIA 10-2474 (a fatty acid amide hydrolase inhibitor) was evaluated in a first-in-human phase 1 study in normal volunteers to assess safety/tolerability, pharmacokinetics, pharmacodynamics, and food effect. The dose-escalation process consisted of a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfa89109e8b3575acf0c0aba0e3c21ab
https://doi.org/10.1002/jcph.889
https://doi.org/10.1002/jcph.889
Publikováno v:
Journal of clinical pharmacologyReferences. 59(10)
Lapatinib, a tyrosine kinase inhibitor, is approved for the treatment of breast cancer. The literature shows that it is metabolized by CYP3A4 and eliminated predominantly (>90%) by the fecal route, with minimal (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01991f57567a6d6393bac30769c6a6a7
https://pubmed.ncbi.nlm.nih.gov/31074516
https://pubmed.ncbi.nlm.nih.gov/31074516
Autor:
Philip Chaikin
Publikováno v:
The Journal of Clinical Pharmacology. 57:1359-1361
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73786f37d33efee2763ef433167c74e2
https://doi.org/10.1002/jcph.1000
https://doi.org/10.1002/jcph.1000
Autor:
Philip Chaikin, Marc R. Gastonguay, Jeannine Fisher, Tatsuo Uchimura, William Knebel, N. Rao, Akihisa Mori
Publikováno v:
The Journal of Clinical Pharmacology. 51:40-52
This model-based analysis quantifies the population pharmacokinetics (PK) of orally administered istradefylline, a selective adenosine A(2A) receptor antagonist, in healthy subjects and patients with Parkinson's disease, including the estimation of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72a42a184f0028addf16fe4ac585d06e
https://doi.org/10.1177/0091270010363809
https://doi.org/10.1177/0091270010363809
Autor:
B. Dvorchik, H. Wang, N. Rao, Philip Chaikin, Akihisa Mori, K. Yamamoto, T. Uchimura, N. Sussman
Publikováno v:
The Journal of Clinical Pharmacology. 48:1092-1098
The effect of steady-state istradefylline, an agent for Parkinson's disease with P-glycoprotein and CYP3A inhibitory activity, on the pharmacokinetics of atorvastatin and its metabolites was evaluated in healthy volunteers. A single 40-mg dose of ato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c2d2014944282e91fc656cb6c440e0
https://doi.org/10.1177/0091270008320924
https://doi.org/10.1177/0091270008320924
Autor:
Philip Chaikin, Sylvain Durrleman
Publikováno v:
Statistics in Medicine. 22:941-952
For life-threatening diseases, ethical considerations preclude the inclusion of an untreated control group in the investigation of a new therapeutic agent when a standard therapy exists. In these cases, active controlled studies are conducted, and ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43269e8f61e573e2b5ac9bfa19780431
https://doi.org/10.1002/sim.1454
https://doi.org/10.1002/sim.1454
Publikováno v:
British Journal of Clinical Pharmacology. 52:201-204
Aims The objective of this study was to compare the effects of high doses of ebastine with terfenadine and placebo on QTc. Methods Thirty-two subjects were randomly assigned to four treatments (ebastine 60 mg day−1, ebastine 100 mg day−1, terfena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6442062bb2810749c4d7968a7429f64
https://doi.org/10.1046/j.0306-5251.2001.01345.x
https://doi.org/10.1046/j.0306-5251.2001.01345.x